Safety and persistence of the humoral and cellular immune responses induced by 2 doses of an AS03-adjuvanted A(H1N1)pdm09 pandemic influenza vaccine administered to infants, children and adolescents: Two open, uncontrolled studies

References

• Dominguez-Cherit G, Lapinsky SE, Macias AE, Pinto R, Espinosa-Perez L, de la Torre A, Poblano-Morales M, Baltazar-Torres JA, Bautista E, Martinez A, et al. Critically Ill patients with 2009 influenza A(H1N1) in Mexico. JAMA 2009; 302:1880-7; PMID:19822626; http://dx.doi.org/10.1001/jama.2009.1536
   PubMed Web of Science ®Google Scholar
• Fraser C, Donnelly CA, Cauchemez S, Hanage WP, Van Kerkhove MD, Hollingsworth TD, Griffin J, Baggaley RF, Jenkins HE, Lyons EJ, et al. Pandemic potential of a strain of influenza A (H1N1): early findings. Science 2009; 324:1557-61; PMID:19433588; http://dx.doi.org/10.1126/science.1176062
   PubMed Web of Science ®Google Scholar
• Novel Swine-Origin Influenza A (H1N1) Virus Investigation Team, Dawood FS, Jain S, Finelli L, Shaw MW, Lindstrom S, Garten RJ, Gubareva LV, Xu X, Bridges CB, et al. Emergence of a novel swine-origin influenza A (H1N1) virus in humans. N Engl J Med 2009; 360:2605-15; PMID:19423869; http://dx.doi.org/10.1056/NEJMoa0903810
   PubMed Web of Science ®Google Scholar
• Bautista E, Chotpitayasunondh T, Gao Z, Harper SA, Shaw M, Uyeki TM, Zaki SR, Hayden FG, Hui DS, Kettner JD, et al. Clinical aspects of pandemic 2009 influenza A (H1N1) virus infection. N Engl J Med 2010; 362:1708-19; PMID:20445182; http://dx.doi.org/10.1056/NEJMra1000449
   PubMed Web of Science ®Google Scholar
• Echevarria-Zuno S, Mejia-Arangure JM, Mar-Obeso AJ, Grajales-Muniz C, Robles-Perez E, Gonzales-Leon M, Ortega-Alvarez MC, Gonzalez-Bonilla C, Rascon-Pacheco RA, Borja-Aburto VH. Infection and death from influenza A H1N1 virus in Mexico: a retrospective analysis. Lancet 2009; 374:2072-9; PMID:19913290; http://dx.doi.org/10.1016/S0140-6736(09)61638-X
   PubMed Web of Science ®Google Scholar
• Kumar A, Zarychanski R, Pinto R, Cook DJ, Marshall J, Lacroix J, Stelfox T, Bagshaw S, Choong K, Lamontagne F, et al. Critically ill patients with 2009 influenza A(H1N1) infection in Canada. JAMA 2009; 302:1872-9; PMID:19822627; http://dx.doi.org/10.1001/jama.2009.1496
   PubMed Web of Science ®Google Scholar
• World Health Organization (Global Alert and Response). Pandemic (H1N1) 2009 - update 94. Accessed April 27, 2015 at: http://www.who.int/csr/don/2010_04_01/en/
   Google Scholar
• World Health Organization (Global Alert and Response). WHO recommendations for the post-pandemic period. Accessed April 27, 2015 at: http://www.who.int/csr/disease/swineflu/notes/briefing_20100810/en/index.html
   Google Scholar
• World Health Organization. Influenza virus infections in humans (February 2014). Accessed April 24, 2015 at: http://www.who.int/influenza/human_animal_interface/virology_laboratories_and_vaccines/influenza_virus_infections_humans_feb14.pdf?ua=1)
   Google Scholar
• Halasa NB. Update on the 2009 pandemic influenza A H1N1 in children. Curr Opin Pediatr 2010; 22:83-7; PMID:20068413; http://dx.doi.org/10.1097/MOP.0b013e3283350317
   PubMed Web of Science ®Google Scholar
• Basta NE, Chao DL, Halloran ME, Matrajt L, Longini IM Jr. Strategies for pandemic and seasonal influenza vaccination of schoolchildren in the United States. Am J Epidemiol 2009; 170:679-86; PMID:19679750; http://dx.doi.org/10.1093/aje/kwp237
   PubMed Web of Science ®Google Scholar
• Loeb M, Russell ML, Moss L, Fonseca K, Fox J, Earn DJ, Aoki F, Horsman G, Van Caeseele P, Chokani K, et al. Effect of influenza vaccination of children on infection rates in Hutterite communities: a randomized trial. JAMA 2010; 303:943-50; PMID:20215608; http://dx.doi.org/10.1001/jama.2010.250
   PubMed Web of Science ®Google Scholar
• Nicoll A. Children, avian influenza H5N1 and preparing for the next pandemic. Arch Dis Child 2008; 93:433-8; PMID:18192315; http://dx.doi.org/10.1136/adc.2006.101477
   PubMed Web of Science ®Google Scholar
• Fiore AE, Neuzil KM. 2009 influenza A(H1N1) monovalent vaccines for children. JAMA 2010; 303:73-4; PMID:20026596; http://dx.doi.org/10.1001/jama.2009.1929
   PubMed Web of Science ®Google Scholar
• Roman F, Vaman T, Gerlach B, Markendorf A, Gillard P, Devaster JM. Immunogenicity and safety in adults of one dose of influenza A H1N1v 2009 vaccine formulated with and without AS03A-adjuvant: preliminary report of an observer-blind, randomised trial. Vaccine 2010; 28:1740-5; PMID:20034605; http://dx.doi.org/10.1016/j.vaccine.2009.12.014
   PubMed Web of Science ®Google Scholar
• Roman F, Vaman T, Kafeja F, Hanon E, Van Damme P. AS03(A)-Adjuvanted influenza A (H1N1) 2009 vaccine for adults up to 85 years of age. Clin Infect Dis 2010; 51:668-77; PMID:20687838; http://dx.doi.org/10.1086/655830
   PubMed Web of Science ®Google Scholar
• European Medicines Agency. EPAR summary for the public: Pandemrix influenza vaccine (H1N1)v (split virion, inactivated, adjuvanted) (accessed June 6th, 2011, at http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Summary_for_the_public/human/000832/WC500038122.pdf)
   Google Scholar
• Fiore AE, Shay DK, Broder K, Iskander JK, Uyeki TM, Mootrey G, Bresee JS, Cox NJ; Centers for Disease Control and Prevention. Prevention and control of seasonal influenza with vaccines: recommendations of the Advisory Committee on Immunization Practices (ACIP), 2009. MMWR Recomm Rep 2009; 58:1-52; PMID:19644442
   PubMedGoogle Scholar
• Carmona A, Omenaca F, Tejedor JC, Merino JM, Vaman T, Dieussaert I, Gillard P, Aristegui J. Immunogenicity and safety of AS03-adjuvanted 2009 influenza A H1N1 vaccine in children 6–35 months. Vaccine 2010; 28:5837-44; PMID:20600478; http://dx.doi.org/10.1016/j.vaccine.2010.06.065
   PubMed Web of Science ®Google Scholar
• Garcia-Sicilia J, Gillard P, Carmona A, Tejedor JC, Aristegui J, Merino JM, Behre U, Caplanusi A, Vaman T, Dieussaert I. Immunogenicity and safety of AS03-adjuvanted H1N1 pandemic vaccines in children and adolescents. Vaccine 2011; 29:4353-61; PMID:21504774; http://dx.doi.org/10.1016/j.vaccine.2011.04.011
   PubMed Web of Science ®Google Scholar
• Clark TW, Pareek M, Hoschler K, Dillon H, Nicholson KG, Groth N, Stephenson I. Trial of 2009 influenza A (H1N1) monovalent MF59-adjuvanted vaccine. N Engl J Med 2009; 361:2424-35; PMID:19745215; http://dx.doi.org/10.1056/NEJMoa0907650
   PubMed Web of Science ®Google Scholar
• Diez-Domingo J, Garces-Sanchez M, Baldo JM, Planelles MV, Ubeda I, Jubert A, Mares J, Moris P, Garcia-Corbeira P, Drame M, et al. Immunogenicity and safety of H5N1 A/Vietnam/1194/2004 (Clade 1) AS03-adjuvanted prepandemic candidate influenza vaccines in children aged 3 to 9 years: a phase ii, randomized, open, controlled study. Pediatr Infect Dis J 2010; 29:e35-e46; PMID:20375709
   PubMed Web of Science ®Google Scholar
• Gillard P, Caplanusi A, Knuf M, Roman F, Walravens K, Moris P, Dramé M, Schwarz TF. An assessment of prime-boost vaccination schedules with AS03A-adjuvanted prepandemic H5N1 vaccines: a randomized study in European adults. Influenza Other Respir Viruses 2013; 7:55-65; PMID:22405557; http://dx.doi.org/10.1111/j.1750-2659.2012.00349.x
   PubMed Web of Science ®Google Scholar
• Roman F, Clement F, Dewe W, Walravens K, Maes C, Willekens J, De Boever F, Hanon E, Leroux-Roels G. Effect on cellular and humoral immune responses of the AS03 adjuvant system in an A/H1N1/2009 influenza virus vaccine administered to adults during two randomized controlled trials. Clin Vaccine Immunol 2011; 18:835-43; PMID:21450978; http://dx.doi.org/10.1128/CVI.00480-10
   PubMed Web of Science ®Google Scholar
• Moris P, van der Most R, Leroux-Roels I, Clement F, Drame M, Hanon E, Leroux-Roels GG, Van Mechelen M. H5N1 Influenza vaccine formulated with AS03(A) induces strong cross-reactive and polyfunctional CD4 T-cell responses. J Clin Immunol 2011; 31:443-54; PMID:21174144; http://dx.doi.org/10.1007/s10875-010-9490-6
   PubMed Web of Science ®Google Scholar
• Heijmans S, De Meulemeester M, Reynders P, Giet D, Demanet E, Devresse PY, Icardi G, Drame M, Roman F, Gillard P. Immunogenicity profile of a 3.75-µg hemagglutinin pandemic rH5N1 split virion AS03A-adjuvanted vaccine in elderly persons: a randomized trial. J Infect Dis 2011; 203:1054-62; PMID:21450995; http://dx.doi.org/10.1093/infdis/jiq174
   PubMed Web of Science ®Google Scholar
• Couch RB, Bayas JM, Caso C, Mbawuike IN, Lopez CN, Claeys C, El Idrissi M, Herve C, Laupeze B, Oostvogels L, Moris P. Superior antigen-specific CD4+ T-cell response with AS03-adjuvantation of a trivalent influenza vaccine in a randomised trial of adults aged 65 and older. BMC Infect Dis 2014; 14:425; PMID:25078387; http://dx.doi.org/10.1186/1471-2334-14-425
   PubMed Web of Science ®Google Scholar
• Gioia C, Castilletti C, Tempestilli M, Piacentini P, Bordi L, Chiappini R, Agrati C, Squarcione S, Ippolito G, Puro V, et al. Cross-subtype immunity against avian influenza in persons recently vaccinated for influenza. Emerg Infect Dis 2008; 14:121-8; PMID:18258091; http://dx.doi.org/10.3201/eid1401.061283
   PubMed Web of Science ®Google Scholar
• Skowronski DM, Hottes TS, McElhaney JE, Janjua NZ, Sabaiduc S, Chan T, Gentleman B, Purych D, Gardy J, Patrick DM, et al. Immuno-epidemiologic correlates of pandemic H1N1 surveillance observations: higher antibody and lower cell-mediated immune responses with advanced age. J Infect Dis 2011; 203:158-67; PMID:21288814; http://dx.doi.org/10.1093/infdis/jiq039
   PubMed Web of Science ®Google Scholar
• Herring A, Hernández Y, Huffnagle G, Toews GB. Role and development of Th1/Th2 immune responses in the lungs. Semin Respir Crit Care Med 2004; 25:3-10; PMID:16088444
   PubMed Web of Science ®Google Scholar
• Rimmelzwaan G, McElhaney JE. Correlates of protection: novel generations of influenza vaccines. Vaccine 2008; 26(suppl 4):D41-4; PMID:19230158; http://dx.doi.org/10.1016/j.vaccine.2008.07.043
   PubMedGoogle Scholar
• Barker CI, Snape MD. Pandemic influenza A H1N1 vaccines and narcolepsy: vaccine safety surveillance in action. Lancet Infect Dis 2014; 14:227-38; PMID:24360892; http://dx.doi.org/10.1016/S1473-3099(13)70238-X
   PubMed Web of Science ®Google Scholar
• Carlander B, Puech-Cathala AM, Jaussent I, Scholz S, Bayard S, Cochen V, Dauvilliers Y. Low vitamin D in narcolepsy with cataplexy. PLoS One 2011; 6:e20433; PMID:21633708; http://dx.doi.org/10.1371/journal.pone.0020433
   PubMedGoogle Scholar
• Han F, Lin L, Warby SC, Faraco J, Li J, Dong SX, An P, Zhao L, Wang LH, Li QY, et al. Narcolepsy onset is seasonal and increased following the 2009 H1N1 pandemic in China. Ann Neurol 2011; 70:410-7; PMID:21866560; http://dx.doi.org/10.1002/ana.22587
   PubMed Web of Science ®Google Scholar
• Aran A, Lin L, Nevsimalova S, Plazzi G, Hong SC, Weiner K, Zeitzer J, Mignot E. Elevated anti-streptococcal antibodies in patients with recent narcolepsy onset. Sleep 2009; 32:979-83; PMID:19725248
   PubMed Web of Science ®Google Scholar
• Dauvilliers Y, Arnulf I, Mignot E. Narcolepsy with cataplexy. Lancet 2007; 369:499-511; PMID:17292770; http://dx.doi.org/10.1016/S0140-6736(07)60237-2
   PubMed Web of Science ®Google Scholar
• Kornum BR, Faraco J, Mignot E. Narcolepsy with hypocretin/orexin deficiency, infections and autoimmunity of the brain. Curr Opin Neurobiol 2011; 21:897-903; PMID:21963829; http://dx.doi.org/10.1016/j.conb.2011.09.003
   PubMed Web of Science ®Google Scholar
• Hehme NW, Künzel W, Petschke F, Türk G, Raderecht C, van Hoecke C, Sanger R. Ten years of experience with the trivalent split-influenza vaccine, Fluarix™. Clin Drug Invest 2002; 22:751-69; http://dx.doi.org/10.2165/00044011-200222110-00004
   Web of Science ®Google Scholar
• Baras B, de Waal L, Stittelaar KJ, Jacob V, Giannini S, Kroeze EJ, van den Brand JM, van Amerongen G, Simon JH, Hanon E, et al. Pandemic H1N1 vaccine requires the use of an adjuvant to protect against challenge in naive ferrets. Vaccine 2011; 29:2120-6; PMID:21238573; http://dx.doi.org/10.1016/j.vaccine.2010.12.125
   PubMed Web of Science ®Google Scholar
• Rowe T, Abernathy RA, Hu-Primmer J, Thompson WW, Lu X, Lim W, Fukuda K, Cox NJ, Katz JM. Detection of antibody to avian influenza A (H5N1) virus in human serum by using a combination of serologic assays. J Clin Microbiol 1999; 37:937-43; PMID:10074505
   PubMed Web of Science ®Google Scholar
• Reed L, Muench H. A simple method of calculating fifty percent end point. Am J Hyg 1938; 27:493-8
   Google Scholar
• Maecker HT, Maino VC, Picker LJ. Immunofluorescence analysis of T-cell responses in health and disease. J Clin Immunol 2000; 20:391-9; PMID:11202228; http://dx.doi.org/10.1023/A:1026403724413
   PubMed Web of Science ®Google Scholar